CYTK Cytokinetics Inc

Price (delayed)

$21.31

Market cap

$1.53B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.02

Enterprise value

$1.71B

Highlights
Cytokinetics's gross profit has soared by 163% YoY and by 4.9% from the previous quarter
The revenue has soared by 163% year-on-year and by 4.9% since the previous quarter
Cytokinetics's quick ratio has decreased by 20% from the previous quarter but it has increased by 11% YoY
The EPS has grown by 9% YoY but it has contracted by 2.5% from the previous quarter
The debt has soared by 64% from the previous quarter and by 62% YoY
CYTK's equity is down by 40% since the previous quarter

Key stats

What are the main financial stats of CYTK
Market
Shares outstanding
71.74M
Market cap
$1.53B
Enterprise value
$1.71B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
22.34
Price to sales (P/S)
25.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29.16
Earnings
Revenue
$58.55M
EBIT
-$119.12M
EBITDA
-$117.16M
Free cash flow
-$7.08M
Per share
EPS
-$2.02
Free cash flow per share
-$0.1
Book value per share
$0.95
Revenue per share
$0.82
TBVPS
$8.11
Balance sheet
Total assets
$577.06M
Total liabilities
$509.22M
Debt
$223.02M
Equity
$67.85M
Working capital
$397.19M
Liquidity
Debt to equity
3.29
Current ratio
12.05
Quick ratio
11.97
Net debt/EBITDA
-1.52
Margins
EBITDA margin
-200.1%
Gross margin
100%
Net margin
-230.5%
Operating margin
-178%
Efficiency
Return on assets
-29.7%
Return on equity
-213.6%
Return on invested capital
-24.5%
Return on capital employed
-22%
Return on sales
-203.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CYTK stock price

How has the Cytokinetics stock price performed over time
Intraday
-2.87%
1 week
1.28%
1 month
-11.06%
1 year
-8.27%
YTD
2.55%
QTD
-8.38%

Financial performance

How have Cytokinetics's revenue and profit performed over time
Revenue
$58.55M
Gross profit
$58.55M
Operating income
-$104.19M
Net income
-$134.99M
Gross margin
100%
Net margin
-230.5%
Cytokinetics's gross profit has soared by 163% YoY and by 4.9% from the previous quarter
The revenue has soared by 163% year-on-year and by 4.9% since the previous quarter
Cytokinetics's operating margin has soared by 62% YoY but it has decreased by 6% from the previous quarter
The net margin has soared by 61% YoY

Growth

What is Cytokinetics's growth rate over time

Valuation

What is Cytokinetics stock price valuation
P/E
N/A
P/B
22.34
P/S
25.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29.16
The EPS has grown by 9% YoY but it has contracted by 2.5% from the previous quarter
CYTK's equity is down by 40% since the previous quarter
The revenue has soared by 163% year-on-year and by 4.9% since the previous quarter
CYTK's P/S is 33% below its last 4 quarters average of 38.7 but 21% above its 5-year quarterly average of 21.4

Efficiency

How efficient is Cytokinetics business performance
The ROS has soared by 63% YoY but it has contracted by 2% from the previous quarter
CYTK's return on invested capital is up by 47% year-on-year and by 15% since the previous quarter
The company's return on assets rose by 47% YoY and by 13% QoQ
The return on equity is up by 42% since the previous quarter

Dividends

What is CYTK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CYTK.

Financial health

How did Cytokinetics financials performed over time
The total assets is 13% greater than the total liabilities
The total assets has surged by 125% year-on-year and by 8% since the previous quarter
Cytokinetics's total liabilities has soared by 68% YoY and by 21% from the previous quarter
Cytokinetics's debt to equity has surged by 174% QoQ
The debt has soared by 64% from the previous quarter and by 62% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.